

10598070

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

10598070

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:04:27 ON 18 JUL 2009

FILE 'REGISTRY' ENTERED AT 08:05:01 ON 18 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUL 2009 HIGHEST RN 1163859-78-6
DICTIONARY FILE UPDATES: 16 JUL 2009 HIGHEST RN 1163859-78-6

New CAS Information Use Policies. Enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10598070a.str



```

chain nodes :
18 19 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 29 30 31 32 33 34
ring/chain nodes :
10
chain bonds :
1-10 5-19 7-18 8-11 22-23 23-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 29-30 29-34 30-31 31-32 32-33 33-34
exact/norm bonds :
1-10 3-9 5-19 7-18 8-9 23-24
exact bonds :
2-7 7-8 8-11 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 29-30
29-34 30-31 31-32 32-33 33-34
isolated ring systems :
containing 1 : 11 :

```

G1:H,CH3

G2:O,OH,N,Hy,Ak

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 22:CLASS
23:CLASS 24:CLASS 28:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS

```

L1 STRUCTURE UPLOADED

10598070

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H, Me
G2 O, OH, N, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sam
SAMPLE SEARCH INITIATED 08:05:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 287 TO ITERATE

100.0% PROCESSED 287 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 4724 TO 6756
PROJECTED ANSWERS: 9 TO 360
```

L2 9 SEA SSS SAM L1

```
=> s 11 ful
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:Y
FULL SEARCH INITIATED 08:05:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED = 6728 TO ITERATE
```

100.0% PROCESSED 6728 ITERATIONS 320 ANSWERS
SEARCH TIME: 00.00.01

L3 320 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 08:05:40 ON 18 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2009 VOL 151 ISS 4

FILE LAST UPDATED: 16 Jul 2009 (20090716/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s 13
L4 116 L3

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.50 186.60

FILE 'REGISTRY' ENTERED AT 08:05:56 ON 18 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUL 2009 HIGHEST RN 1163859-78-6
DICTIONARY FILE UPDATES: 16 JUL 2009 HIGHEST RN 1163859-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when

10598070



conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10598070a.str



chain nodes :

18 19 22 23 24

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 29 30 31 32 33 34

ring/chain nodes :

10

chain bonds :

1-10 5-19 7-18 8-11 22-23 23-24

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 29-30 29-34 30-31 31-32 32-33 33-34

exact/norm bonds :

1-10 3-9 5-19 7-18 8-9 23-24

exact bonds :

2-7 7-8 8-11 22-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 29-30
29-34 30-31 31-32 32-33 33-34

isolated ring systems :

containing 1 : 11 :

G1:H,CH3

G2:O,OH,N,Hy,Ak

10598070

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 22:CLASS
23:CLASS 24:CLASS 28:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



G1 H, Me

G2 O, OH, N, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sub=13

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 44.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SUBSET SEARCH INITIATED 08:07:13 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 314 TO ITERATE

100.0% PROCESSED 314 ITERATIONS
SEARCH TIME: 00.00.01

247 ANSWERS


L6 247 SEA SUB=L3 SSS FUL L5

=> d scan

10598070

L6 247 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Butanamide, N-hydroxy-4-[[1-[[4-[[4-[[1R]-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]-4-piperidinyl]amino]-
MF C30 H37 N7 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

10598070

L6 247 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Propanamide, N-hydroxy-3-[[4-[4-[[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]methyl]amino]-
MF C24 H26 N6 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10598070

L6 247 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(3-methylphenyl)methyl]-6-[4-(1-pyrrolidinylmethyl)phenyl]-
MF C25 H27 N5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10598070

L6 247 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(1R)-1-(4-chlorophenyl)ethyl]-6-[4-(4-morpholinylmethyl)phenyl]-
MF C25 H26 Cl N5 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10598070

=> d hist

(FILE 'HOME' ENTERED AT 08:04:27 ON 18 JUL 2009)

FILE 'REGISTRY' ENTERED AT 08:05:01 ON 18 JUL 2009

L1 STRUCTURE UPLOADED
L2 9 S L1 SAM
L3 320 S L1 FUL

FILE 'CPLUS' ENTERED AT 08:05:40 ON 18 JUL 2009

L4 116 S L3

FILE 'REGISTRY' ENTERED AT 08:05:56 ON 18 JUL 2009

L5 STRUCTURE UPLOADED
L6 247 S L5 SUB=L3 FUL

=> s l3 not l6

L7 73 L3 NOT L6

=> fil cap1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.88	233.48

FILE 'CPLUS' ENTERED AT 08:09:34 ON 18 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2009 VOL 151 ISS 4

FILE LAST UPDATED: 16 Jul 2009 (20090716/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references

10598070

information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

```
=> s 17
L8          3 L7

=> s 18 not (2009/so or 2008/so or 2007/so or 2006/so)
    449293 2009/SO
    953331 2008/SO
    996130 2007/SO
    950110 2006/SO
L9          3 L8 NOT (2009/SO OR 2008/SO OR 2007/SO OR 2006/SO)


=> s 19 not us20070135460/pn
    1 US20070135460/PN
L10         2 L9 NOT US20070135460/PN

=> d 110 ibib hitstr abs 1-2
```

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:1060779 CAPLUS
 DOCUMENT NUMBER: 142:38274
 TITLE: Preparation of 7H-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors
 INVENTOR(S): Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio; Traxler, Peter
 PATENT ASSIGNEE(S): Novartis AG, Switz.
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 485,747.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040248911	A1	20041209	US 2004-783000	20040220
US 7323469	B2	20080129		
WO 2003013541	A1	20030220	WO 2002-EP8780	20020806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 20040242600	A1	20041202	US 2004-485747	20040203
US 7244729	B2	20070717		
PRIORITY APPLN. INFO.:			GB 2001-19249	A 20010807
			WO 2002-EP8780	W 20020806
			US 2004-485747	A2 20040203

OTHER SOURCE(S): MARPAT 142:38274
 IT 497840-89-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (claimed compound; preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)
 RN 497840-89-8 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
 N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




IT 497840-90-1P 497840-91-2P 497840-92-3P
 497840-93-4P 497840-94-5P 497840-95-6P
 497840-96-7P 497840-97-8P 497840-98-9P
 497840-99-0P 497841-00-6P 497841-01-7P
 497841-02-8P 497841-04-0P 497841-05-1P
 497841-06-2P 497841-07-3P 497841-08-4P
 497841-09-5P 497841-10-8P 497841-11-9P
 497841-12-0P 497841-13-1P 497841-14-2P
 497841-15-3P 497841-16-4P 497841-17-5P
 497841-18-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)


RN 497840-90-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
 N-(6-methoxy-3-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-
 (CA INDEX NAME)




10598070

RN 497840-91-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 497840-92-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 497840-93-4 CAPLUS
CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)

10598070




RN 497840-94-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[(6-[(4-[(dimethylamino)methyl]phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-95-6 CAPLUS

CN 2(1H)-Pyridinone, 5-[(6-[(4-[(dimethylamino)methyl]phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-96-7 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-97-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[(4-[(4-ethyl-1-piperazinyl)methyl]phenyl)-N-[(6-methoxy-3-pyridinyl)methyl]]- (CA INDEX NAME)




RN 497840-98-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (CA
INDEX NAME)




RN 497840-99-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (CA
INDEX NAME)




RN 497841-00-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (CA INDEX NAME)




RN 497841-01-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 497841-02-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]-
(CA INDEX NAME)




RN 497841-04-0 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-05-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-06-2 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-07-3 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-08-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-09-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-10-8 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-11-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX
NAME)




RN 497841-12-0 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497841-13-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-
(CA INDEX NAME)




RN 497841-14-2 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497841-15-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)-
(CA INDEX NAME)




RN 497841-16-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-
(CA INDEX NAME)




RN 497841-17-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (CA INDEX NAME)

RN 497841-18-6 CAPLUS

CN 2-(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)



IT 497841-51-7P 497841-52-8P 497841-54-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyrrolopyrimidines as protein tyrosine kinase inhibitors)


RN 497841-51-7 CAPLUS

CN Benzoic acid, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 497841-52-8 CAPLUS

CN Benzenemethanol, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 497841-54-0 CAPLUS

CN Benzenemethanol, 4-[4-[(2-methoxy-4-pyridinyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)



GI




AB Title compds. [I; R₁, R₂ = H, (substituted) alkyl, cycloalkyl, heterocyclyl, R₄Y(C:Z); R₄ = (substituted) amino, heterocyclyl; Y = null, alkyl; Z = O, S, imino; R₁R₂N = heterocyclyl; R₃ = heterocyclyl, (substituted) aryl; G = alkylene, CO, alkylene carbonyl; Q = NH, CO; X = null, alkylene; with provisos], were prepared. Thus, (3-chloro-4-fluorophenyl)-[6-[4-(4-ethylpiperazin-1-ylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine (preparation outlined) inhibited the tyrosine kinase activity of HER-1, HER-2, and KDR with IC₅₀ = 0.0031 μ M, 0.008 μ M, and 0.0107 μ M, resp.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:133054 CAPLUS
 DOCUMENT NUMBER: 138:170253
 TITLE: Preparation of
 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein
 tyrosine kinase inhibitors
 INVENTOR(S): Bold, Guido; Capraro, Hans-Georg; Caravatti, Giorgio;
 Traxler, Peter
 PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013541	A1	20030220	WO 2002-EP8780	20020806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2453881	A1	20030220	CA 2002-2453881	20020806
AU 2002324029	A1	20030224	AU 2002-324029	20020806
AU 2002324029	B2	20050127		
EP 1416935	A1	20040512	EP 2002-758437	20020806
EP 1416935	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011801	A	20040831	BR 2002-11801	20020806
HU 2004001083	A2	20040928	HU 2004-1083	20020806
HU 2004001083	A3	20071228		
CN 1538847	A	20041020	CN 2002-815351	20020806
JP 2005501077	T	20050113	JP 2003-518550	20020806
JP 4147184	B2	20080910		
NZ 530824	A	20050826	NZ 2002-530824	20020806
RU 2318826	C2	20080310	RU 2004-106783	20020806
AT 388713	T	20080315	AT 2002-758437	20020806
ES 2302830	T3	20080801	ES 2002-758437	20020806
ZA 2004000271	A	20041101	ZA 2004-271	20040114
US 20040242600	A1	20041202	US 2004-485747	20040203
US 7244729	B2	20070717		
NO 2004000540	A	20040205	NO 2004-540	20040205
MX 2004001191	A	20050217	MX 2004-1191	20040206
IN 2004CN00238	A	20051209	IN 2004-CN238	20040206
US 20040248911	A1	20041209	US 2004-783000	20040220
US 7323469	B2	20080129		
HK 1065483	A1	20080822	HK 2004-108357	20041025
US 20070161632	A1	20070712	US 2007-686023	20070314
US 7390805	B2	20080624		
PRIORITY APPLN. INFO.:			GB 2001-19249	A 20010807
			WO 2002-EP8780	W 20020806
			US 2004-485747	A2 20040203

OTHER SOURCE(S): MARPAT 138:170253
 IT 497840-89-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)
 RN 497840-89-8 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
 N-(6-methoxy-3-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




IT 497840-90-1P 497840-91-2P 497840-92-3P
 497840-93-4P 497840-94-5P 497840-95-6P
 497840-96-7P 497840-97-8P 497840-98-9P
 497840-99-0P 497841-00-6P 497841-01-7P
 497841-02-8P 497841-03-9P 497841-04-0P
 497841-05-1P 497841-06-2P 497841-07-3P
 497841-08-4P 497841-09-5P 497841-10-8P
 497841-11-9P 497841-12-0P 497841-13-1P
 497841-14-2P 497841-15-3P 497841-16-4P
 497841-17-5P 497841-18-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)
 RN 497840-90-1 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
 N-(6-methoxy-3-pyridinyl)-6-[4-(4-methyl-1-piperazinyl)methyl]phenyl- (CA INDEX NAME)




RN 497840-91-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)- (CA INDEX
NAME)




RN 497840-92-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(6-methoxy-3-pyridinyl)-
(CA INDEX NAME)




RN 497840-93-4 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




CN 2(1H)-Pyridinone, 5-[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-95-6 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-96-7 CAPLUS

CN 2(1H)-Pyridinone, 5-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497840-97-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]- (CA INDEX NAME)




RN 497840-98-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(6-methoxy-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX NAME)




RN 497840-99-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-[(6-methoxy-3-pyridinyl)methyl]-
(CA INDEX NAME)




RN 497841-00-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]- (CA INDEX NAME)




RN 497841-01-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]- (CA
INDEX NAME)




RN 497841-02-8 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxy-4-pyridinyl)methyl]-
(CA INDEX NAME)



RN 497841-03-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-[(2-methoxy-4-pyridinyl)methyl]-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (CA INDEX NAME)




RN 497841-04-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[[[6-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-05-1 CAPLUS

CN 2 (1H)-Pyrnidinone, 5-[[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino)methyl]- (CA INDEX NAME)




RN 497841-06-2 CAPLUS

CN 2 (1H)-Pyridinone, 5-[[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-07-3 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-08-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-09-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-10-8 CAPLUS

CN 2(1H)-Pyridinone, 4-[[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]methyl]- (CA INDEX NAME)




RN 497841-11-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-(2-methoxy-4-pyridinyl)-6-[4-(4-morpholinylmethyl)phenyl]- (CA INDEX
NAME)




RN 497841-12-0 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-(4-morpholinylmethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497841-13-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
N-(2-methoxy-4-pyridinyl)-6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-
(CA INDEX NAME)




RN 497841-14-2 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)




RN 497841-15-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)-
(CA INDEX NAME)




RN 497841-16-4 CAPLUS

CN 2(1H)-Pyridinone, 4-[[6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-
(CA INDEX NAME)




RN 497841-17-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
6-[4-[(dimethylamino)methyl]phenyl]-N-(2-methoxy-4-pyridinyl)- (CA INDEX NAME)

RN 497841-18-6 CAPLUS

CN 2-(1H)-Pyridinone, 4-[[6-[4-[(dimethylamino)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]- (CA INDEX NAME)



IT 497841-51-7P 497841-52-8P 497841-54-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)


RN 497841-51-7 CAPLUS

CN Benzoic acid, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 497841-52-8 CAPLUS

CN Benzenemethanol, 4-[4-[(6-methoxy-3-pyridinyl)methyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)




RN 497841-54-0 CAPLUS


CN Benzenemethanol, 4-[4-[(2-methoxy-4-pyridinyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)



GI



I



II

AB The title compds. I [R1, R2 = H, alkyl, cycloalkyl, etc.; or NR1R2 = heterocyclyl; R3 = heterocyclyl, (un)substituted aryl; G = alkylene, CO, alkyleneCO wherein the carbonyl group is attached to the NR1R2; Q = NH, O, with the proviso that Q = O if G = CO or alkyleneCO; X is either not present or alkylene, with the proviso that a heterocyclic radical R3 is bonded via a ring carbon if X is not present] and their salts, useful for treatment of a disease which responds to an inhibition of a protein tyrosine kinase, especially for the treatment of a proliferative disease, such as a tumor, were prepared and formulated. E.g., a 4-step synthesis of II, starting from Et 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoate and 3-chloro-4-fluoroaniline, was given. Compds. I were tested for their inhibition of the tyrosine kinase activity of EGF-R (HER-1), ErbB-2 (HER-2) and VEGF receptor (KDR) (data given for 21 exemplified compds.).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT